01
Specialist launch
85%
Into 85% of relevant formularies in 7 months, 65% over commercial forecast within a year.
Insight.Access.Adoption.
NHS market access for pharma and healthcare leaders.
We reach the payers others can't - and turn access into adoption.
How Accessus Works
Accelerating
Access
A different NHS
demands a
different model
Commissioning has consolidated.
The 2026 ICB mergers have already redrawn the decision-making map, and a further wave follows in 2027. Fewer, larger commissioners now hold more of the power over local access.
Accessus is built for this NHS.
From pharma ambition
to NHS operational reality
16%
UK product adoption - 3 years post NICE approval
The challenge in healthcare isn't developing innovation - it's delivering it. As the gap between approval and implementation grows, Accessus Group helps pharmaceutical companies turn innovation into adoption.
Not every product requires NICE approval but the access challenge is the same - getting the NHS to adopt. That's where we work.
Source: ABPI Competitiveness Framework, 2025 (ABPI analysis of Office for Life Sciences, Life Sciences Competitiveness Indicators 2024; England only).
“Having the Accessus team has been pivotal to our launch success. Originally, I wanted to build the capability in-house - the results meant I didn’t have to.”
From Approval to Adoption
Our Proven Results: different launches, different markets. One outcome: adoption in months, not years.
02
Primary care market launch
230%
Listed across all London ICB formularies and 90% of Trusts in 8 months. Growing 230% in 12 months.
03
First-in-class launch
90%
Delivered to over 90% of NHS regions. 84% of UK patients gained access inside 6 months of NICE approval.
Latest Research
Decoding UK Payers:
what 50 senior payers told us.
We asked 50 senior NHS payers where industry engagement falls short and what better looks like.
The answers are a clear agenda for change.
“The survey and final report were
turned around incredibly fast
and high quality, with clear,
actionable takeaways. It’s
allowed us to accelerate the
impact of our investments.”
Frequently
asked questions.
It's a gap that's getting wider. Approval is national, but adoption happens area by area, through each ICB's formulary, budget and pathway decisions. 42 of 50 senior payers tell us that implementation work lands on the NHS, not industry. Without support, adoption stalls. Accessus helps close that gap.
The senior decision-makers with real influence over local access: ICB medicines and commissioning leads, hospital chief pharmacists and medical directors, specialised commissioning and finance leads. Whether we're gathering their insight or engaging them directly, these are the people who shape whether your product is adopted.
Yes. Our research runs in full compliance with BHBIA guidelines, and our wider work adheres to the ABPI code. Compliance is built into how we work, not bolted on.
Most in-house and agency teams reach the same engaged payers and work largely remotely. Accessus reaches the senior decision-makers others can't, and works across the whole access journey: insight into how payers think, a commercial strategy they can say yes to, and face-to-face engagement that moves decisions. As one client put it, they'd planned to build the capability in-house, but the results meant they didn't have to.
Chat, Connect and Consult can be offered as independent services. Most clients start with Chat, because the insight shapes and sharpens everything that follows.
Find out what senior NHS payers really think
Tell us who you need to hear from.
We’ll tell you how fast we can get you the answer.
“…an invaluable partner for me and added significant value to projects that I have managed.”